1
Country: USA | Funding: $135.5M
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
2
Country: USA | Funding: $114.3M
SafelyYou is the artificial intelligence-enabled fall detection and prevention for dementia care.
SafelyYou is the artificial intelligence-enabled fall detection and prevention for dementia care.
3
Country: USA | Funding: $55M
Rippl, a mental health organization, is committed to assisting seniors who suffer from dementia and other neurocognitive disorders.
Rippl, a mental health organization, is committed to assisting seniors who suffer from dementia and other neurocognitive disorders.
4
Country: Germany | Funding: $6.7M
Lindera has developed the 1st quantitative mobility self-test for seniors by analyzing the gait to prevent falls.
Lindera has developed the 1st quantitative mobility self-test for seniors by analyzing the gait to prevent falls.
5
Country: Sweden | Funding: SEK15M
Geras Solutions aims to provide a clear pathway towards a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia supportive solutions via an easy to use mobile health tool.
Geras Solutions aims to provide a clear pathway towards a reliable dementia specialist that is time and cost-effective. The Geras Solutions App offers individuals living with dementia and carers an ecosystem of digital dementia supportive solutions via an easy to use mobile health tool.
6
Country: Germany
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
Priavoid envisions curing neurological disorders by developing innovative treatment strategies based on a new class of orally available compounds. Focusing on indications with significant unmet medical need Priavoid applies the therapeutic concept to Alzheimer’s disease (AD), neuropathic pain and other neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), tauopathies, Parkinson’s disease (PD), and Huntington’s disease (HD).
